OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Showing 26-50 of 116 citing articles:
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study
Sailish Honap, Bénédicte Caron, Jacob E. Ollech, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Sailish Honap, Bénédicte Caron, Jacob E. Ollech, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Real-world experience with switching from originator to biosimilar natalizumab
Einar A. Høgestøl, Åge Winje Brustad, Elisabeth Gulowsen Celius, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Einar A. Høgestøl, Åge Winje Brustad, Elisabeth Gulowsen Celius, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Susan Richards, Insa Winzenborg, Doreen Luedtke, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
Céleste J T van der Togt, Bart J. F. van den Bemt, Daniel Aletaha, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002898-e002898
Open Access | Times Cited: 15
Céleste J T van der Togt, Bart J. F. van den Bemt, Daniel Aletaha, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002898-e002898
Open Access | Times Cited: 15
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study
Sung Noh Hong, Joo Hye Song, Sung Jin Kim, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 4, pp. 517-528
Closed Access | Times Cited: 14
Sung Noh Hong, Joo Hye Song, Sung Jin Kim, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 4, pp. 517-528
Closed Access | Times Cited: 14
Biomarkers and biologics related with psoriasis and psoriatic arthritis
Weize Gao, Zhan Wang, Wenshuai Li, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110646-110646
Closed Access | Times Cited: 12
Weize Gao, Zhan Wang, Wenshuai Li, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110646-110646
Closed Access | Times Cited: 12
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
W Kantasiripitak, An Outtier, Sebastian G. Wicha, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 11, Iss. 8, pp. 1045-1059
Open Access | Times Cited: 20
W Kantasiripitak, An Outtier, Sebastian G. Wicha, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 11, Iss. 8, pp. 1045-1059
Open Access | Times Cited: 20
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
Karine Rodríguez-Fernández, Víctor Mangas‐Sanjuán, Matilde Merino‐Sanjuán, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 654-654
Open Access | Times Cited: 17
Karine Rodríguez-Fernández, Víctor Mangas‐Sanjuán, Matilde Merino‐Sanjuán, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 654-654
Open Access | Times Cited: 17
Training the next generation of pharmacometric modelers: a multisector perspective
Peter L. Bonate, Jeffrey S. Barrett, Sihem Ait‐Oudhia, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2023) Vol. 51, Iss. 1, pp. 5-31
Closed Access | Times Cited: 9
Peter L. Bonate, Jeffrey S. Barrett, Sihem Ait‐Oudhia, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2023) Vol. 51, Iss. 1, pp. 5-31
Closed Access | Times Cited: 9
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
C. Krieckaert, Borja Hernández‐Breijo, Johanna Elin Gehin, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002216-e002216
Open Access | Times Cited: 14
C. Krieckaert, Borja Hernández‐Breijo, Johanna Elin Gehin, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002216-e002216
Open Access | Times Cited: 14
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Fernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 7, pp. 1102-1112
Closed Access | Times Cited: 2
Fernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 7, pp. 1102-1112
Closed Access | Times Cited: 2
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline
Letícia Kawano-Dourado, Eirik Klami Kristianslund, Dena Zeraatkar, et al.
BMJ (2024), pp. e079830-e079830
Closed Access | Times Cited: 2
Letícia Kawano-Dourado, Eirik Klami Kristianslund, Dena Zeraatkar, et al.
BMJ (2024), pp. e079830-e079830
Closed Access | Times Cited: 2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
The pathogenesis and targeted therapies of intervertebral disc degeneration induced by cartilage endplate inflammation
Haiyan Yang, Xiaoyan Chen, Jun Chen, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Haiyan Yang, Xiaoyan Chen, Jun Chen, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Camilla de Almeida Martins, Karoline Soares Garcia, Natália Sousa Freitas Queiroz
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Camilla de Almeida Martins, Karoline Soares Garcia, Natália Sousa Freitas Queiroz
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Patient and Family Representation in Randomized Clinical Trials Published in 3 Medical and Surgical Journals
Nissim Benizri, Sophie Hallot, Karen E. A. Burns, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2230858-e2230858
Open Access | Times Cited: 12
Nissim Benizri, Sophie Hallot, Karen E. A. Burns, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2230858-e2230858
Open Access | Times Cited: 12
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial
Yaara Zisman‐Ilani, Kimberly D. Thompson, Lori S. Siegel, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 2, pp. 205-214
Open Access | Times Cited: 12
Yaara Zisman‐Ilani, Kimberly D. Thompson, Lori S. Siegel, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 2, pp. 205-214
Open Access | Times Cited: 12
